Galeterone
Overview[edit | edit source]
Galeterone is an investigational drug that was developed for the treatment of prostate cancer. It is a small molecule that acts as an androgen receptor antagonist, CYP17A1 inhibitor, and androgen receptor degrader. Galeterone was designed to target multiple pathways involved in the progression of castration-resistant prostate cancer (CRPC).
Mechanism of Action[edit | edit source]
Galeterone works through a multi-faceted mechanism:
- It inhibits the CYP17A1 enzyme, which is crucial for the synthesis of androgens. By inhibiting this enzyme, galeterone reduces the production of androgens that can stimulate prostate cancer growth.
- It acts as an antagonist to the androgen receptor, blocking the binding of androgens to the receptor and thereby inhibiting the androgen receptor signaling pathway.
- It promotes the degradation of the androgen receptor, reducing the number of receptors available for activation by androgens.
Development and Clinical Trials[edit | edit source]
Galeterone was developed by Tokai Pharmaceuticals and underwent several phases of clinical trials. The drug showed promise in early-stage trials, particularly in patients with specific genetic mutations such as AR-V7, a splice variant of the androgen receptor that is associated with resistance to other therapies.
However, in later-stage clinical trials, galeterone did not demonstrate sufficient efficacy compared to existing treatments, leading to the discontinuation of its development for prostate cancer.
Potential Benefits and Challenges[edit | edit source]
The potential benefits of galeterone included its ability to target multiple mechanisms of androgen receptor signaling, which could theoretically overcome resistance seen with other therapies that target only one aspect of the pathway.
Challenges in the development of galeterone included the complexity of its mechanism of action and the need to demonstrate clear clinical benefits over existing therapies such as abiraterone and enzalutamide.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
